Aspirin-free care with ticagrelor after a heart attack treated without stents or bypass
Part of Heart & circulation clinical trials.
This trial tests whether taking ticagrelor (a blood thinner) alone, without aspirin, is safe and effective for people who have had a heart attack and are being treated with medication only (no stents or bypass surgery). It could mean fewer pills and possibly reduce bleeding risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were hospitalized for a type 1 heart attack (caused by a blocked artery)
- You had a coronary angiogram (a dye test of your heart arteries)
- You are being treated with medications only, without a stent or bypass surgery
- You are willing to come to study follow-up visits
- Your doctor expects you to live at least 1 more year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
This trial tests whether a lower dose of aspirin is safe and effective for patients who have had a heart attack (STEMI) and received a stent. If you've been taking aspirin and ticagrelor after your procedure, you may be able to join.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This trial tests whether switching to a simpler antiplatelet medication (ticagrelor) after a mild stroke or high-risk TIA can prevent another stroke while reducing the risk of bleeding. It is for people who have not received clot-busting treatment or had a large stroke.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This trial compares two common blood-thinning medications (prasugrel vs ticagrelor) and two treatment durations (short 1–3 months vs standard 12 months) after a heart attack treated with stents. It aims to find the most effective and safest anti-clotting strategy for patients.
Hear when a new NSTEMI - Non-ST Segment Elevation MI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.